Literature DB >> 25806319

Update on third-generation EGFR tyrosine kinase inhibitors.

Jhanelle Gray1, Eric Haura1.   

Abstract

Entities:  

Year:  2014        PMID： 25806319      PMCID： PMC4367680          DOI： 10.3978/j.issn.2218-6751.2014.09.08

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  6 in total

1.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Authors:  Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; Shucai Zhang; Jie Wang; Songwen Zhou; Shengxiang Ren; Shun Lu; Li Zhang; Chengping Hu; Chunhong Hu; Yi Luo; Lei Chen; Ming Ye; Jianan Huang; Xiuyi Zhi; Yiping Zhang; Qingyu Xiu; Jun Ma; Li Zhang; Changxuan You
Journal:  Lancet Oncol       Date:  2011-07-23       Impact factor: 41.316

2.  Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

Authors:  Yelena Y Janjigian; Christopher G Azzoli; Lee M Krug; Leanne K Pereira; Naiyer A Rizvi; M Catherine Pietanza; Mark G Kris; Michelle S Ginsberg; William Pao; Vincent A Miller; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2011-01-19       Impact factor: 12.531

3.  Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Authors:  David Jackman; William Pao; Gregory J Riely; Jeffrey A Engelman; Mark G Kris; Pasi A Jänne; Thomas Lynch; Bruce E Johnson; Vincent A Miller
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

4.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

5.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

6.  LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.

Authors:  Nobuyuki Katakami; Shinji Atagi; Koichi Goto; Toyoaki Hida; Takeshi Horai; Akira Inoue; Yukito Ichinose; Kunihiko Koboyashi; Koji Takeda; Katsuyuki Kiura; Kazuto Nishio; Yoko Seki; Ryuichi Ebisawa; Mehdi Shahidi; Nobuyuki Yamamoto
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544
  6 in total
  4 in total

Review 1.  Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management.

Authors:  Jonathan W Goldman; Melody A Mendenhall; Sarah R Rettinger
Journal:  Oncologist       Date:  2016-07-29

2.  Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report.

Authors:  Wenhua Liang; Qihua He; Ying Chen; Shaokun Chuai; Weiqiang Yin; Wei Wang; Guilin Peng; Caicun Zhou; Jianxing He
Journal:  BMC Cancer       Date:  2016-02-05       Impact factor: 4.430

3.  Design, Synthesis, and Evaluation of Ribose-Modified Anilinopyrimidine Derivatives as EGFR Tyrosine Kinase Inhibitors.

Authors:  Xiuqin Hu; Disha Wang; Yi Tong; Linjiang Tong; Xia Wang; Lili Zhu; Hua Xie; Shiliang Li; You Yang; Yufang Xu
Journal:  Front Chem       Date:  2017-11-15       Impact factor: 5.221

Review 4.  Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy.

Authors:  Leanne G Ahronian; Ryan B Corcoran
Journal:  Genome Med       Date:  2017-04-21       Impact factor: 11.117
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.